Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 57, Issue 7

Issues

Increased prevalence of anti-DFS70 antibodies in young females: experience from a large international multi-center study on blood donors

Roger Albesa / Ulrich Sachs
  • Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maria Infantino
  • Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Laboratory Medicine, Florence, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Mariangela Manfredi
  • Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Laboratory Medicine, Florence, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maurizio Benucci / Yvonne Baus / Silke Lutterbeck / Luis AndradeORCID iD: https://orcid.org/0000-0001-8742-9931 / Kieran Morris / Alice Friedenberg / Silvia Casas / Xavier Bossuyt
  • KU Leuven Department of Microbiology and Immunology, Leuven, Belgium
  • University Hospitals Leuven, Department of Laboratory Medicine, Leuven, Belgium
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Michael Mahler
  • Corresponding author
  • Inova Diagnostics, INC, 9900 Old Grove Road, San Diego, CA 32131-1638, USA, Phone/Fax: +858 586 9900/858 586 9911
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-02-11 | DOI: https://doi.org/10.1515/cclm-2018-1233

Abstract

Background

Isolated antibodies to DFS70 have been described in healthy individuals and are rarely found in patients with antinuclear antibody-associated autoimmune rheumatic diseases (AARD). However, no data is available on geographic differences in the prevalence of anti-DFS70 antibodies. We aimed to study the prevalence of anti-DFS70 antibodies in blood donor samples from several countries representing various ethnical backgrounds and geographic regions in the world.

Methods

Sera from apparently healthy blood donors (n≥300 per site) were collected in seven countries (USA, Italy, Spain, Germany, UK, Belgium and Brazil). All samples (n=2628) were tested for anti-DFS70 antibodies by QUANTA Flash DFS70 (Inova Diagnostics, Inc., San Diego, CA, USA).

Results

The prevalence of anti-DFS70 antibodies varied from 4/321 (1.2%, Italy) to 42/497 (8.5%, USA). Consequently, the prevalence of the antibodies was significantly higher in USA compared to all other countries (p<0.05). In addition, the prevalence in the combined cohort (all sites) was higher in young blood donors (<35 years; 5.0% vs. 2.7%; p=0.0017) and among females (4.5% vs. 3.0%; p=0.0446). However, when cohorts from different countries were corrected for age and gender, no significant difference between the countries were found.

Conclusions

This is the first study to analyze the prevalence of anti-DFS70 antibodies in different geographic areas using a standardized assay. Our findings show that the antibodies are most prevalent in young females.

Keywords: antinuclear antibodies; autoantibodies; autoimmune disease; DFS; LEDGF

References

  • 1.

    Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci 2010;1183:267–87.CrossrefPubMedGoogle Scholar

  • 2.

    Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014;2014:315179.Web of SciencePubMedGoogle Scholar

  • 3.

    Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010;69:1420–2.CrossrefWeb of SciencePubMedGoogle Scholar

  • 4.

    Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000;105:1211–20.CrossrefPubMedGoogle Scholar

  • 5.

    Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? Arthritis Rheum 2004;50:684–8.CrossrefPubMedGoogle Scholar

  • 6.

    Ochs RL, Stein TW, Jr., Peebles CL, Gittes RF, Tan EM. Autoantibodies in interstitial cystitis. J Urol 1994;151:587–92.CrossrefPubMedGoogle Scholar

  • 7.

    Shinohara T, Singh DP, Chylack LT, Jr. Review: Age-related cataract: immunity and lens epithelium-derived growth factor (LEDGF). J Ocul Pharmacol Ther 2000;16:181–91.CrossrefPubMedGoogle Scholar

  • 8.

    Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005;62:14–26.PubMedCrossrefGoogle Scholar

  • 9.

    Maertens G, Cherepanov P, Pluymers W, Busschots K, De CE, Debyser Z, et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 2003;278:33528–39.PubMedCrossrefGoogle Scholar

  • 10.

    Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892–900.CrossrefPubMedGoogle Scholar

  • 11.

    Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011;63:191–200.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 12.

    Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol 2012;2012:494356.Web of ScienceGoogle Scholar

  • 13.

    Conrad K, Rober N, Andrade LE, Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol 2017;52:202–16.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 14.

    Ayaki M, Ohoguro N, Azuma N, Majima Y, Yata K, Ibaraki N, et al. Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmunity 2002;35:319–27.PubMedCrossrefGoogle Scholar

  • 15.

    Muro Y, Sugiura K, Morita Y, Tomita Y. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus 2008;17:171–6.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 16.

    Mahler M, Hanly JG, Fritzler MJ. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev 2011;11:642–5.Web of ScienceGoogle Scholar

  • 17.

    Shovman O, Gilburd B, Chayat C, Amital H, Langevitz P, Watad A, et al. Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clin Exp Rheumatol 2017;36:121–6.PubMedGoogle Scholar

  • 18.

    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.PubMedCrossrefGoogle Scholar

  • 19.

    Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger TA, Jr., et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64:358–67.PubMedCrossrefGoogle Scholar

  • 20.

    Narain S, Richards HB, Satoh M, Sarmiento M, Davidson R, Shuster J, et al. Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. Arch Intern Med 2004;164:2435–41.PubMedCrossrefGoogle Scholar

  • 21.

    Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526–33.PubMedCrossrefGoogle Scholar

  • 22.

    Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapaa-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011;13:R30.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 23.

    Fritzler MJ. The antinuclear antibody test: last or lasting gasp? Arthritis Rheum 2011;63:19–22.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 24.

    Dellavance A, Cancado EL, Abrantes-Lemos CP, Harriz M, Marvulle V, Andrade LE. Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatol Int 2013;7:775–84.Web of ScienceCrossrefPubMedGoogle Scholar

  • 25.

    Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012;39:2104–10.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 26.

    Mahler M, Radice A, Sinico RA, Damoiseaux J, Seaman A, Buckmelter K, et al. Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study. Nephrol Dial Transplant 2011;27:243–52.Web of SciencePubMedGoogle Scholar

  • 27.

    Mahler M, Radice A, Yang W, Bentow C, Seaman A, Bianchi L, et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta 2012;413:719–26.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 28.

    Mahler M, Ngo JT, Schulte-Pelkum J, Luettich T, Fritzler MJ. Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther 2008;10:R131.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 29.

    Bizzaro N, Tonutti E, Villalta D. Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: not an easy task! Comment on the article by Mariz et al. Arthritis Rheum 2011;63:4036–7.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 30.

    Zheng B, Li E, Zhu H, Lu J, Shi X, Zhang J, et al. Automated antinuclear immunofluorescence antibody analysis is a reliable approach in routine clinical laboratories. Clin Chem Lab Med 2017;55:1922–30.Web of SciencePubMedGoogle Scholar

  • 31.

    Infantino M, Shovman O, Perez D, Grossi V, Manfredi M, Benucci M, et al. A better definition of the anti-DFS70 antibody screening by IIF methods. J Immunol Methods 2018;461:110–6.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 32.

    Bentow C, Fritzler MJ, Mummert E, Mahler M. Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Auto Immun Highlights 2016;7:8.CrossrefPubMedGoogle Scholar

  • 33.

    Guo YP, Wang CG, Liu X, Huang YQ, Guo DL, Jing XZ, et al. The prevalence of antinuclear antibodies in the general population of china: a cross-sectional study. Curr Ther Res Clin Exp 2014;76:116–9.CrossrefGoogle Scholar

  • 34.

    Choi MY, Clarke AE, St PY, Hanly JG, Urowitz MB, Romero-Diaz J, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus 2017;26:1051–9.Web of ScienceCrossrefGoogle Scholar

  • 35.

    Mahler M, Meroni PL, Andrade LE, Khamashta M, Bizzaro N, Casiano CA, et al. Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmun Rev 2016;15:198–201.Web of ScienceCrossrefPubMedGoogle Scholar

  • 36.

    Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011;7:170–8.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 37.

    Gundin S, Irure-Ventura J, Asensio E, Ramos D, Mahler M, Martinez-Taboada V, et al. Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Auto Immun Highlights 2016;7:10.PubMedCrossrefGoogle Scholar

About the article

Received: 2018-11-08

Accepted: 2018-12-27

Published Online: 2019-02-11

Published in Print: 2019-06-26


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: X. Bossuyt received consultant fees from Inova Diagnostics.

Employment or leadership: R. Albesa, M. Mahler, Y. Baus, S. Lutterbeck and S. Casas are employed at Inova Diagnostics selling autoantibody assays.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 57, Issue 7, Pages 999–1005, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2018-1233.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Maria Infantino, Francesca Pregnolato, Chelsea Bentow, Michael Mahler, Maurizio Benucci, Francesca Li Gobbi, Arianna Damiani, Valentina Grossi, Franco Franceschini, Caterina Bodio, Maria Orietta Borghi, and Mariangela Manfredi
Clinical Chemistry and Laboratory Medicine (CCLM), 2019, Volume 0, Number 0
[2]
May Y. Choi and Marvin J. Fritzler
Current Treatment Options in Rheumatology, 2019, Volume 5, Number 2, Page 147

Comments (0)

Please log in or register to comment.
Log in